Gavin M A, Gilbert M J, Riddell S R, Greenberg P D, Bevan M J
Department of Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
J Immunol. 1993 Oct 15;151(8):3971-80.
The characterization of the epitopes recognized by CTL provides insights into the nature of protective immune responses and facilitates the development of methods to enhance immunity to human pathogens. However, no easily applicable approach for CTL epitope identification has been developed. We present a rapid and efficient method for locating CTL epitopes within a protein. The gene encoding the protein of interest is inserted into an inducible prokaryotic expression vector. Random peptides are then generated by alkali digestion of intact or lysed Escherichia coli expressing the protein and assayed for the presence of the epitope by coating target cells for a standard CTL targeting assay. A large panel of clones containing serial 3'-deletions of the gene is then generated by exonuclease III digestion, and the expressed truncated proteins are similarly analyzed for the presence of the antigenic peptide. The epitope is located by determining the deletion points of clones expressing sequential truncations and differing in Ag expression. This technique was used to identify the H-2Ld-restricted nonamer in E. coli beta-galactosidase, with residues 876-884 representing the naturally processed epitope. To test the applicability of this method to other proteins, two genes from human CMV, an often fatal pathogen in immunocompromised individuals, were screened for HLA class I-restricted epitopes. An HLA-B18-restricted epitope from the CMV major immediate-early protein was found to lie between residues 378 and 389, and an HLA-B35-restricted epitope from the CMV pp65 matrix protein was characterized as residues 123 to 131. The results demonstrate that this technique can be used to rapidly identify CTL epitopes within a chosen protein and should be useful for assaying viral isolates or neoplasms for loss of epitopes after mutation and selection by host immune responses.
对细胞毒性T淋巴细胞(CTL)识别的表位进行表征,有助于深入了解保护性免疫反应的本质,并推动增强对人类病原体免疫力方法的开发。然而,目前尚未开发出易于应用的CTL表位鉴定方法。我们提出了一种在蛋白质中定位CTL表位的快速有效方法。将编码目标蛋白质的基因插入可诱导的原核表达载体中。然后通过对表达该蛋白质的完整或裂解的大肠杆菌进行碱消化来产生随机肽,并通过包被靶细胞进行标准的CTL靶向测定来检测表位的存在。然后通过核酸外切酶III消化产生一大组包含该基因3'-连续缺失的克隆,并对表达的截短蛋白进行类似的抗原肽存在分析。通过确定表达连续截短且抗原表达不同的克隆的缺失点来定位表位。该技术用于鉴定大肠杆菌β-半乳糖苷酶中H-2Ld限制性九肽,其中876-884位氨基酸代表天然加工的表位。为了测试该方法对其他蛋白质的适用性,筛选了人类巨细胞病毒(CMV,免疫功能低下个体中常见的致命病原体)的两个基因中的HLA I类限制性表位。发现来自CMV主要立即早期蛋白的HLA-B18限制性表位位于378至389位氨基酸之间,来自CMV pp65基质蛋白的HLA-B35限制性表位被鉴定为123至131位氨基酸。结果表明,该技术可用于快速鉴定所选蛋白质中的CTL表位,对于检测病毒分离株或肿瘤在宿主免疫反应的突变和选择后表位的丧失应该是有用的。